LiCellMo — Paving the Way for Metabolic Research and Cell & Gene Therapy*

Live cell metabolic analysis paves the way not only for metabolic research, but also the manufacturing of significant CGT products.

The investigation and understanding of cellular metabolism has become increasingly important in recent years. In the expanding fields of cancer immunotherapy, stem cell research, and commercial biological manufacturing process development, greater metabolic control is resulting in more effective outcomes and higher quality end products. In the field of cancer immunotherapy — such as CAR-T and TCR-T therapy, stem cell research including embryonic stem (ES) and induced pluripotent stem (iPS) cells and commercial cell and gene therapy (CGT) manufacturing process development — all require investigating and understanding the metabolic activities of cells which are critical.

Learn more: https://www.phchd.com/us/biomedical/live-cell-metabolic-analyzer

* Product not yet commercially available
Outcome in Caucasian patients with hepatitis B e antigen negative chronic infection: A long-term observational cohort study

Özgür M. Koc1,2,3,4 | Geert Robaeys1,2,5 | Halit Topal6 | Rob Bielen1,2 | Dana Busschots1,2 | Johan Fevery5 | Ger H. Koek4,7,8 | Frederik Nevens5

1Department of Gastroenterology and Hepatology, Ziekenhuis Oost-Limburg, Genk, Belgium
2Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium
3Department of Medical Microbiology, Medical Centre, Maastricht University, Maastricht, The Netherlands
4School of Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University, Maastricht, The Netherlands
5Department of Gastroenterology and Hepatology, University Hospitals KU Leuven, Leuven, Belgium
6Department of Abdominal Surgery, University Hospitals KU Leuven, Leuven, Belgium
7Department of Internal Medicine, Division of Gastroenterology and Hepatology, Medical Centre, Maastricht University, Maastricht, The Netherlands
8Department of Visceral Surgery and Transplantation, University Hospital of the RWTH, Aachen, Germany

Correspondence Özgür M. Koc, Faculty of Medicine and Life Sciences, Hasselt University, Martelarenlaan 42, 3500 Hasselt, Belgium.
Email: ozgur.koc@uhasselt.be

Abstract
Sensitive polymerase chain reaction assays to measure hepatitis B virus (HBV) DNA became only available the last decade. Hence, the long-term outcome of Caucasian patients in Western Europe with hepatitis B e antigen (HBeAg)-negative chronic infection, especially with a baseline HBV DNA level \( \geq 2000 \) IU/mL, is still unclear. Out of a cohort of 1936 chronic HBV patients, 413 Caucasian individuals were identified with HBeAg-negative chronic infection, defined as persistently normal alanine aminotransferase (ALT) levels and HBV DNA levels <20 000 IU/mL. During a mean follow-up of 12 years, 366 (88.6%) maintained an HBeAg-negative chronic infection status, whereas 25 (6.1%) developed chronic active hepatitis (CAH). In total, Nine of these 25 CAH cases were related to immunosuppression. In total, 22 (5.3%) individuals had ALT > 2 \( \times \) upper limit of normal due to non-HBV-related causes. The cumulative probability of spontaneously developing CAH after 10 years was almost exclusively seen in patients with baseline HBV DNA level \( \geq 2000 \) IU/mL (11.7% vs 1.2%; \( P < .001 \)). Advanced liver disease developed significantly more in patients with baseline HBV DNA level \( \geq 2000 \) IU/mL (5.2% vs 1.5%; \( P = .018 \)) and occurred especially in patients with obesity (16.7% vs 4.2%; \( P = .049 \)). The incidence of hepatocellular carcinoma was 0.0%. Caucasian patients with HBeAg-negative chronic infection and baseline HBV DNA level <2000 IU/mL have an excellent long-term prognosis in the absence of immunosuppressive therapy. However, patients with baseline HBV DNA level \( \geq 2000 \) IU/mL are at risk to develop advanced liver disease.

KEYWORDS
alanine aminotransferase, Caucasian race, chronic hepatitis B, HBeAg-negative chronic infection, HBV DNA, inactive HBV carrier

Abbreviations: ALT, alanine aminotransferase; anti-HBe, antibodies against HBeAg; CAH, chronic active hepatitis; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; NASH, nonalcoholic steatohepatitis; PCR, polymerase chain reaction; qHBsAg, quantitative HBsAg; ULN, upper limit of normal.
1 | INTRODUCTION

Infection with hepatitis B virus (HBV) remains a global health challenge with approximately 257 million people living with chronic HBV infection, of whom 887,000 die annually from HBV-related complications such as cirrhosis and hepatocellular carcinoma (HCC). The natural history of chronic HBV infection can be divided in four phases, taking into account the presence of hepatitis B e antigen (HBeAg), serum HBV DNA levels, and serum alanine aminotransferase (ALT) values.2–4

One of these phases is the HBeAg-negative chronic infection state.4 This stage was previously called "inactive carrier" phase, but this terminology was abandoned since previous studies indicated that some of these patients developed advanced liver disease.5

According to current management guidelines on hepatitis B, therapy is not indicated in patients with HBeAg-negative chronic infection but follow-up for the risk of HBV reactivation, advanced liver disease, and HCC is recommended.2–4 Most evidence on the natural history of HBeAg-negative chronic infection is based on studies in Asian patients, wherein the high sensitivity of polymerase chain reaction (PCR)-based HBV DNA assays has contributed to our understanding that even low HBV DNA levels may still be associated with the risk of liver disease progression.5–7 However, only a limited number of studies have assessed the risk of disease progression and its predictors in Caucasian patients. Previous European studies on the natural history of patients in the chronic infection phase were limited by the short duration of follow-up (less than 10-year follow-up), small groups of patients (<200 subjects), poorly defined criteria for HBeAg-negative chronic infection, and the use of the low sensitivity branched HBV DNA assays for quantification.8–18

Recent sensitive PCR assays to measure HBV DNA have demonstrated that, in general, patients with HBeAg-negative chronic infection have HBV DNA levels <2000 IU/mL. However, some patients in this phase have HBV DNA levels between 2000 and 20,000 IU/mL.3–4 The risk of liver disease progression is unclear in this subgroup of Caucasian patients with baseline HBV DNA levels ≥2000 IU/mL.

This is the first long-term follow-up study of more than 10 years in HBeAg-negative Caucasian patients making use of the high sensitive PCR-based assays. The main objectives were to investigate the disease outcome of those with HBV DNA levels ≥2000 IU/mL and to find out whether a cut-off value of serum HBV DNA level of 2000 IU/mL can predict those patients who would benefit from a strict follow-up program and those who do not require a stringent monitoring.

2 | PATIENTS AND METHODS

The study involved three large educational hospitals, two in Belgium and one in the Netherlands. The data were to be collected according to a protocol that followed the strengthening the reporting of observational studies in epidemiology statement with clear definitions of the study population, follow-up, and outcome data.

2.1 | Study population

The study identified all consecutive chronic HBV patients of the participating centers between 1 January 1987 and 31 July 2018 who fulfilled the following inclusion criteria: (a) Caucasian race, (b) persistence of HBsAg for at least 1 year, (c) the presence of antibodies to HBeAg (anti-HBe) without HBeAg, (d) low HBV DNA (<20,000 IU/mL), (e) persistently normal ALT levels, defined as ≥3 ALT determinations (≤40 IU/L) at least 2 months apart over a period of at least 12 months,2–4 and (f) follow-up at the enrolling center for a minimum period of 12 months. Patients previously treated with HBV antiviral agents were excluded as well as HBsAg-positive patients with prophylactic administration of antiviral therapy. Other exclusion criteria were: (a) signs of significant fibrosis (F2 based on transient elastography values >9.0 kPa or liver biopsy), (b) patients with hepatitis D or HIV co-infection, (c) a history of significant alcohol consumption based on a threshold of 14 units per week in men and 7 units per week in women,20 and (d) evidence of coexisting liver disease (eg, nonalcoholic steatohepatitis [NASH], autoimmune hepatitis).

2.2 | Follow-up

The observation period was calculated from the date of presentation until death or the last visit at the outpatient clinic. At the first visit in the outpatient clinic, a complete history was taken, a physical examination was conducted, and liver disease activity and severity were assessed including markers of HBV infection (eg, HBeAg and anti-HBe, HBV DNA).4 Biochemical parameters and an abdominal ultrasound were recommended in all patients. Patients were monitored with periodical determinations of serum ALT and HBV DNA levels as well as for liver stiffness by transient elastography from 2006 onwards. Liver biopsy was not routinely advised and only performed in case of suspected advanced liver disease (based on laboratory results, abdominal ultrasound, and/or transient elastography) and in the suspicion of a concomitant liver disease.20 Results from transient elastography and liver biopsies were evaluated according to the META VIR classification.21

2.3 | Definition of clinical events

The primary outcome was the development of chronic active hepatitis (CAH), defined by increased ALT levels to more than twice the upper limit of normal (ULN) on two occasions at least 2 weeks apart with HBV DNA levels ≥2000 IU/mL whether or not with HBeAg reversion.2–4 Increased ALT levels >2 x ULN that could not be classified as CAH were designated as non-HBV-related cause.22

According to the report of the Baveno VI Consensus Workshop, advanced liver disease was suspected on transient elastography values >10 kPa.23 The development of cirrhosis was defined as a clinical syndrome consisting of either histological confirmation of
Cirrhosis was further classified according to the Child-Pugh score. HCC diagnosis was based on noninvasive criteria (positive lesion detected by at least two different imaging techniques) or pathology. In addition, this study evaluated the incidence of mortality and liver-related mortality.

### 2.4 Immunosuppressive treatment

This study also assessed whether patients who developed a CAH were exposed to immunosuppressive or cancer chemotherapy. The immunosuppressive therapies were classified into those with low (eg, azathioprine), moderate (cyclosporine), and high (eg, rituximab, high-dose corticosteroids, infliximab) risk of reactivation as previously outlined by Loomba and Liang. CAH resulting from immunosuppressive therapy was considered up to 6 months after cessation of immunosuppression, and in the case of B-cell depleting drugs (eg, rituximab) as late as 12 months posttreatment.

### 2.5 Laboratory procedures

ALT and viral markers (HBsAg, antibodies to HBsAg [anti-HBs], HBeAg, anti-HBe, hepatitis C and D virus antibodies, anti-HIV) were determined using conventional serological assays. Serum samples at baseline were stored at −20°C. Up to 2002, serum HBV DNA levels were analysed on stored serum samples with the branched DNA signal amplification assay (Chiron Diagnostics, Emeryville, CA) lower limit of detection of 0.7 mEq/mL (7.00 × 10^5 IU/mL). Thereafter, HBV DNA quantification was performed by ABI Prism 7900HT (Applied Biosystems, Thermo Fisher Scientific, Waltham, MA) with a detection limit of 100 IU/mL and from 2015 on by a commercial PCR assay (Abbott RealTime HBV assay; Abbott Molecular Inc, Des Plaines, IL) with a sensitivity of 10 IU/mL. Serum qHBsAg was measured on the Elecsys HBsAg II quant (Roche Diagnostics, Penzberg, Germany) or Architect HBsAg QT (Abbott Diagnostics, IL) assay.

### 2.6 Statistical analysis

Statistical analysis was performed with the SPSS software version 25 (IBM Corp, Armonk, NY). Continuous variables are expressed as mean ± standard deviation or medians + interquartile range as appropriate. For the comparison of categorical variables, either the χ² test or the Fisher’s exact test was used. The Student t test or Mann-Whitney U nonparametric test was used to analyse continuous variables between two independent groups. The level of statistical significance was set at P < .05 in two-tailed tests.

Estimates on the rate of CAH and advanced liver disease were calculated using the Kaplan-Meier method, and the difference was determined using the logrank test. Univariate analyses (logrank tests) to identify variables associated with CAH or advanced liver disease included age at diagnosis (<40 vs ≥40 years), sex (male vs female), obesity (yes vs no), baseline ALT level (low-normal < 0.5 × ULN vs high-normal 0.5 – 1 × ULN), baseline quantitative HBsAg (qHBsAg) level (<1000 vs ≥1000 IU/mL) and baseline HBV DNA level (<2000 vs ≥2000 IU/mL). Multivariate Cox regression analysis was not performed due to expected data sparseness, that is, CAH and advanced liver disease were not expected to occur in all converges of the abovementioned variables.

### 2.7 Ethical approval

Following the Belgian law of 7 May 2004, an approval of an ethics committee is not necessary for a retrospective non-interventional study.

### 3 RESULTS

Out of 1936 patients with chronic HBV infection at baseline, we identified 413 Caucasians with HBeAg-negative chronic infection according to in and exclusion criteria of this study (Figure 1). The baseline characteristics of the 413 included Caucasian patients were as follows: mean age at presentation was 34 ± 13.6 years; 210 (50.8%) were males and 81 (19.6%) had a baseline HBV DNA level ≥2000 IU/mL. Additional information on qHBsAg level was available in 146 of 413 (35.4%) patients. In patients with detectable viremia in which genotyping could be performed: 36 of 61 (59.0%) had a genotype A and 25 of 61 (41.0%) a genotype D.

### 3.1 Chronic active hepatitis

During a mean follow-up of 12 ± 8.3 years, 366 (88.6%) of 413 patients maintained HBeAg-negative chronic infection, whereas 25 (6.1%) developed CAH. The remaining 22 (5.3%) individuals had ALT level > 2 × ULN of non-HBV-related cause (eg, nonalcoholic fatty liver disease, medication use, malignant infiltration). Of the 25 patients with CAH, 9 were considered to be the result from immunosuppressive therapy or cancer chemotherapy. Five patients received immunosuppressive therapy with a moderate risk of hepatitis B reactivation, that is, two patients were the result from post-kidney transplant immunosuppression and three were in the setting of cancer treatment. In addition, three patients with lymphoma received rituximab containing regimens and one subject was treated with high-dose (>20 mg orally daily) corticosteroids for rheumatic disease.

Table 1 illustrates the baseline characteristics of the 404 Caucasian patients after excluding those nine patients with CAH due to immunosuppressive therapy. Thus, the prevalence of spontaneous development to CAH in the study population was 16 of 404 (4.0%) (Figure 1).
The cumulative probabilities of CAH development were 1 of 283 (0.4%), 7 of 196 (3.6%), and 8 of 131 (6.1%) at 5, 10, and 15 years follow-up, respectively. In univariate analyses (logrank tests) among the 404 Caucasian patients, baseline HBV DNA level \( \geq 2000 \text{IU/mL} \) (11.7% vs 1.2%; \( P < .001 \)) and qHBsAg level \( \geq 1000 \text{IU/mL} \) (7.1% vs 1.0%; \( P = .015 \)) were the only factors significantly associated with the occurrence of CAH. Figure 2 shows the cumulative probabilities of spontaneous CAH development in two groups, that is, baseline HBV DNA levels <2000IU/mL and those with baseline HBV DNA levels \( \geq 2000 \text{IU/mL} \). Among patients with baseline HBV DNA level \( \geq 2000 \text{IU/mL} \) (n = 77), qHBsAg level \( \geq 1000 \text{IU/mL} \) identified patients with a higher risk to develop CAH (\( P = .002 \)): it was 28.6% for patients with a qHBsAg level \( \geq 1000 \text{IU/mL} \) and 0.0% if qHBsAg level <1000IU/mL.

**Figure 1** Study flowchart. ALD, advanced liver disease; ALT, alanine aminotransferase; CAH, chronic active hepatitis; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; ULN, upper limit of normal

**Table 1** Baseline characteristics of 404 Caucasian patients with hepatitis B e antigen negative chronic infection

| Characteristics                                      | All (n = 404) | Remained HBeAg-negative chronic infection (n = 366) | CAH (n = 16) | \( P \) value |
|------------------------------------------------------|---------------|---------------------------------------------------|------------|--------------|
| Baseline age, y                                      | 34 ± 13.5     | 34 ± 13.3                                         | 31 ± 12.2  | .511         |
| Sex, males, %                                        | 205 (50.7)    | 181 (49.5)                                        | 10 (62.5)  | .307         |
| Obesity\(^a\), %                                     | 32 (7.9)      | 27 (7.4)                                          | 1 (6.3)    | 1.000        |
| Baseline ALT, IU/L                                   | 24 ± 8.2      | 24 ± 8.2                                          | 25 ± 7.4   | .427         |
| Baseline qHBsAg level, IU/mL\(^b,c\)                 | 365 ± 2010.7  | 362 ± 1613.9                                      | 1965 ± 5788,0 | .525       |
| Baseline HBV DNA, log IU/mL\(^d\)                    | 2.3 ± 3.11    | 2.3 ± 3.09                                        | 3.3 ± 0.69 | .003         |
| HBV DNA >2000 IU/mL, %                               | 77 (19.1)     | 64 (17.5)                                         | 9 (56.3)   | .001         |

Note: Values shown as mean ± standard deviation or as n (%).

A total of 366 individuals remained HBeAg-negative chronic infection, 16 developed spontaneous CAH, while the remaining 22 patients had increased ALT levels > 2 × ULN of non-HBV-related cause.

Abbreviations: ALT, alanine aminotransferase; CAH, chronic active hepatitis B; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; qHBsAg, quantification of hepatitis B surface antigen; ULN, upper limit of normal.

\(^a\)Obesity was defined as BMI >30 kg/m\(^2\).

\(^b\)Mann-Whitney U nonparametric test was used instead and median ± interquartile range were shown as appropriate.

\(^c\)Information on qHBsAg was available in 146 of 404 (36.1%), 130 of 366 (35.5%), and 6 of 16 (37.5%) among all 404 patients, patients who remained HBeAg-negative chronic infection and those with spontaneous CAH development, respectively.
3.2 | Follow-up of serum HBV DNA levels and HBsAg

Longitudinal follow-up of serum HBV DNA levels revealed that HBV DNA levels exceeded 2000 IU/mL in 151 of 404 (37.4%) Caucasian patients during follow-up vs 77 of 404 (19.1%) at baseline and that 35 of 404 (8.7%) patients developed an HBV DNA level ≥ 20 000 IU/mL. Spontaneous HBsAg loss occurred in 0.94 per 100 persons-years. The cumulative incidences of HBsAg loss were 9 of 291 (3.1%), 19 of 206 (9.2%), and 32 of 145 (22.1%) at 5, 10, and 15 years follow-up, respectively. HBsAg loss was 11.5% in the group with HBV DNA level < 2000 IU/mL and 4.9% in those with HBV DNA ≥ 2000 IU/mL, P = .080. In the group of patients with HBsAg loss (n = 42), anti-HBs appeared in 29 (69.0%) patients. The cumulative appearances of anti-HBs for 1, 2, 5, and 10 years were 5.1% (2 of 39), 13.2% (5 of 38), 40.0% (14 of 35), and 59.4% (19 of 32).

3.3 | Clinical outcome

A total of 73 (18.1%) out of the 404 Caucasian patients underwent percutaneous liver biopsy during follow-up on suspicion of progressive liver disease. Histologically proven advanced liver disease was present in 5 of 73 (6.8%) patients. Overall, the cumulative probabilities of advanced liver disease were 0 of 285 (0.0%), 2 of 195 (1.0%), and 4 of 127 (3.1%) at 5, 10, and 15 years of follow-up, respectively.

Risk predictors for advanced liver disease in the univariate analyses (logrank tests) among the 404 patients were male sex (3.9% vs 0.5%; P = .029; File S1) and baseline HBV DNA level ≥ 2000 IU/mL (5.2% vs 1.5%; P = .018). Among patients with baseline HBV DNA level ≥ 2000 IU/mL (n = 77), obesity was associated with a higher risk of advanced liver disease (16.7% vs 4.2%; P = .049). In the group of patients with baseline HBV DNA level < 2000 IU/mL (n = 327), none of the variables were significantly associated with a lower risk of progression to advanced liver disease. Figure 3 illustrates the progression to advanced liver disease in patients with baseline HBV DNA level < 2000 IU/mL against those with baseline HBV DNA levels ≥ 2000 IU/mL.

In total, 6 of 404 patients (1.5%) developed cirrhosis. Five had Child-Pugh score A and one died due to acute-on-chronic liver failure. There were no reports of HCC. The mean time to cirrhosis development was 17 ± 4.5 years.

A total of 381 of 404 (94.3%) were alive at the end of follow-up. Death occurred in 23 (5.7%) patients and among 4 of them reason of death was unknown. In the remaining 19 patients, there was 1 liver-related mortality reported. Malignant neoplasms were the leading cause of death, accounting for nine cases of death. Chronic obstructive pulmonary disease, myocardial infarction, pneumonia, end-stage renal disease, and enteric fever explained the remaining 10 deaths.

4 | DISCUSSION

The term “inactive carrier” for patients with HBeAg-negative chronic infection was abandoned as Asian studies demonstrated that even low HBV DNA levels may still be associated with the risk of liver disease progression. Moreover, the number of patients with baseline HBV DNA levels ≥ 2000 IU/mL in the previous studies was small (n = 4-46),. In the current cohort, 81 patients had a baseline HBV DNA level ≥ 2000 IU/mL. In line with our findings, Papatheodoridis et al. confirmed the relation between baseline HBV DNA level ≥ 2000 IU/mL and the risk of HBV reactivation in patients in Greece.
Recent data have shown that hepatitis B surface antigen quantification might be helpful in the decision on the frequency of follow-up in such patients. However, this test is not routinely available in daily practice. In line with prior studies, our patients—in which we could do this test—had a median qHBsAg level <1000 IU/mL and qHBsAg level could identify patients at higher risk of progression in the subgroup with baseline HBV DNA level \( \geq 2000 \text{ IU/mL} \).

As a consequence of the growing obesity epidemic, more and more chronic HBV patients with coexisting NASH are expected. NASH is an independent risk factor for cirrhosis and HCC, and in our study obesity was also a risk factor for advanced liver disease among those patients with baseline HBV DNA level \( \geq 2000 \text{ IU/mL} \).

We could also confirm that CAH was triggered by immunosuppressive therapy or cancer chemotherapy. In that respect, we found that immunosuppression was associated with the development of CAH in more than one-third of the patients, underlying the importance of screening for hepatitis B before starting immunosuppressive therapies.

One limitation of the current study is that variables such as genotype, precore/core mutations, and platelets level were not included in the current study to assess their association with disease progression. Genotype and precore/core mutations are not routinely determined in standard practice. After all, this study aimed to investigate the long-term disease outcome and their predictors among

### FIGURE 2

Cumulative probabilities of spontaneous chronic active hepatitis development by baseline hepatitis B virus DNA level (n = 404). A total of 404 Caucasian patients with HBeAg-negative chronic infection were analysed after excluding nine individuals with immunosuppression-related CAH occurrence. Among this group, progression to CAH was higher in patients with baseline HBV DNA level \( \geq 2000 \text{ IU/mL} \) than in patients with baseline HBV DNA level <2000 IU/mL (\( P < .001 \), logrank test). Cumulative probabilities of CAH were 1 of 53 (1.9%) vs 0 of 229 (0.0%), 5 of 32 (15.6%) vs 1 of 162 (0.6%), and 6 of 24 (25.0%) vs 1 of 105 (1.0%) at 5, 10, and 15 years follow-up, respectively.

\( ^{†} \) Patients were censored on the date of last outpatient clinic visit. HBeAg, hepatitis B e antigen; CAH, chronic active hepatitis.
Caucasian patients with HBeAg-negative chronic infection in real-life daily practice.

In conclusion, Caucasian patients from Western Europe with HBeAg-negative chronic infection and baseline HBV DNA levels <2000 IU/mL have a favorable condition without any risk of HCC and with a cumulative incidence of HBsAg loss of approximately 10%. This is in contrast to patients with baseline HBV DNA levels ≥2000 IU/mL who are, especially in the presence of obesity, at risk for advanced liver disease.

**ACKNOWLEDGMENTS**

This study is part of the "Limburg Clinical Research Program", supported by the foundation Limburg Sterk Merk, province of Limburg, Flemish government, Hasselt University, Ziekenhuis Oost-Limburg and Jessa Hospital. The authors would like to thank for Natalie Van den Ende for the data management.

**CONFLICT OF INTERESTS**

The authors declare that there are no conflict of interests.
REFERENCES

1. World Health Organization. Hepatitis B. Geneva, Switzerland: WHO; 2018. Available at: http://www.who.int/mediacentre/factsheets/fs204/en/. Accessed 6 March 2019.

2. Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1-98.

3. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560-1599.

4. European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-398.

5. Lai M, Hyatt BJ, Nasser I, Curry M, Afdhal NH. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol. 2007;47(6):760-767.

6. Ikeda K, Arase Y, Saitoh S, et al. Long term outcome of HBV carriers with negative HBe antigen and normal aminotransferase. Am J Med. 2006;119(11):977-985.

7. Chen CJ. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295(1):65-73.

8. Martinot-Perignoux M, Boyer N, Colombat M, et al. Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. J Hepatol. 2002;36(4):546-546.

9. Papatheodoridis GV, Chrysanthos N, Hadziyannis E, Cholongitas E, Manesis EK. Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection. J Viral Hepat. 2008;15(6):434-441.

10. Papatheodoridis GV, Manesis EK, Manolakopoulos S, et al. Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection? Hepatology. 2008;48(5):1451-1459.

11. Oliveri F, Surace L, Cavallone D, et al. Long-term outcome of inactive and active, low viraemic HBeAg-negative hepatitis B virus infection: Benign course towards HBsAg clearance. Liver Int. 2017;37(11):1622-1631.

12. Gigi E, Lalla T, Orphanou E, Sinakos E, Vrettou E, Raptopoulou-Gigi M. Long term follow-up of a large cohort of inactive HBsAg (+)/HBeAg (-)/anti-HBe (+) carriers in Greece. J Gastroenterol Hepatol. 2007;16(1):19-22.

13. Manno M, Cammà C, Schepsis F, et al. Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. Gastroenterology. 2004;127(3):756-763.

14. Fattovich G, Olivari M, Pasino M, D’Onofrio M, Martone E, Donato F. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut. 2008;57(1):84-90.

15. de Franchis R. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med. 1993;118(3):191-194.

16. Manesis EK, Papatheodoridis GV, Sebastiano V, Cholongitas E, Papaioannou C, Hadziyannis SJ. Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection. Am J Gastroenterol. 2003;98(10):2261-2267.

17. Zacharakis G, Koskinas J, Kotisaou S, et al. The role of serial measurement of serum HBV DNA levels in patients with chronic HBeAg(-) hepatitis B infection: association with liver disease progression: a prospective cohort study. J Hepatol. 2008;49(6):884-891.

18. Villeneuve JP, Desrochers M, Infante-Rivard C, et al. A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal. Gastroenterology. 1994;106(4):1000-1005.

19. Papatheodoridis GV, Manolakopoulos S, Liaw YF, Lok A. Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review. J Hepatol. 2012;57(1):196-202.

20. European Association for the Study of the Liver. EASL clinical practice guidelines: management of alcohol-related liver disease. J Hepatol. 2018;69(1):154-181.

21. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C: the META VIR Cooperative Study Group. Hepatology. 1996;24(2):289-293.

22. Chu CM, Hung SJ, Lin J, Tai DI, Liaw YF. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med. 2004;116(12):829-834.

23. de Franchis R. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatology. 2015;63(3):743-752.

24. Infante-Rivard C, Esnaola S, Villeneuve JP. Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhotics. Hepatology. 1987;7(4):660-664.

25. Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology. 2017;152(6):1297-1309.

26. Seto WK, Chan TSY, Hwang YY, et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol. 2014;32(33):3736-3743.

27. Cornberg M, Wong VW, Locarnini S, Brunetto M, Janssen HLA, Chan HL. The role of quantitative hepatitis B surface antigen retested. J Hepatol. 2017;66(2):398-411.

28. Verhaegh P, Bavaia R, Winkens B, Mascele A, Jonkers D, Koek G. Noninvasive tests do not accurately differentiate nonalcoholic steatohepatitis from simple steatosis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16(6):837-61.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Koc ÖM, Robaey G, Topal H, et al. Outcome in Caucasian patients with hepatitis B e antigen negative chronic infection: A long-term observational cohort study. J Med Virol. 2020;92:3373-3380. https://doi.org/10.1002/jmv.25950